A Case of Pulmonary Arterial Hypertension Associated with Congenital Extrahepatic Portocaval Shunt

Jeong-Eun Yi,1 Hae-Ok Jung,1 Ho-Joong Youn,1 Jong Young Choi,2 Ho Jong Chun,3 and Jae Young Lee4

1Division of Cardiology, Department of Internal Medicine, 2Division of Hepatology, Department of Internal Medicine, Departments of 3Radiology and 4Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea

Received: 18 July 2013 Accepted: 26 September 2013

Address for Correspondence:
Hae-Ok Jung, MD
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea
Tel.: +82.2-2208-6031; Fax: +82.2-591-1506
E-mail: hojheart@catholic.ac.kr

INTRODUCTION

Congenital extrahepatic portocaval shunt (CEPS) is a congenital anomaly observed predominantly in females in which the splanchinic blood bypasses the liver and drains directly into the inferior vena cava (IVC). After the first description of this entity by Abernethy in 1793, fewer than 30 cases of CEPS have been reported (1). Pulmonary hypertension related to CEPS is an extremely rare condition: to date, only a few cases have been reported in the medical literature (2, 3). Here we present a case of CEPS in an adult male, which has not been described previously.

CASE DESCRIPTION

In October 2012, a 20-yr-old male was referred to our department with pulmonary hypertension of unknown etiology. He underwent surgical closure of ventricular septal defect (VSD) at 10 months of age. Eleven months before admission, the patient underwent laparoscopic appendectomy at another hospital. During the preoperative evaluation, screening abdominal ultrasound (US) showed multiple liver masses, and transthoracic Doppler echocardiography (TTE) showed pulmonary hypertension of unknown origin.

On admission, the patient had mild exertional dyspnea (New York Heart Association, NYHA class II). Physical examination revealed pectus excavatum but was otherwise unremarkable. Laboratory values were within normal limits except for slightly reduced serum total protein (6.3 g/dL; reference range, 6.6-8.3) and mildly elevated direct bilirubin (0.53 mg/dL; reference range, 0.13-0.47) and blood ammonia (105 μg/dL; reference range, 20-80). Serologic markers for hepatitis B and C virus and for AFP and CA-19 were negative.

TTE showed a significantly dilated right ventricle (RV) chamber with a D-shaped left ventricle (LV). The LV chamber was mildly dilated, but the LV ejection fraction was normal. The estimated RV systolic pressure (RVSP), calculated as the maximal velocity of tricuspid regurgitation (TR Vmax), was 64 mmHg, which indicated moderate pulmonary hypertension (Fig. 2). We found no definite shunt flow through the inter-ventricular or inter-atrial septum and main pulmonary artery. In addition, there was no evidence of pulmonary thromboembolism or pericardial effusion. These findings were confirmed by transesophageal echocardiography (TEE).

Cardiac catheterization was performed to confirm the diagnosis and to classify the pulmonary hypertension based on the Dana Point classification recommended by the World Health Organization (WHO) (4, 5). Right catheterization, performed with a Cournand catheter, showed a pulmonary capillary wedge
pressure (PCWP) of 7 mmHg, mean pulmonary arterial pressure (mPAP) of 44 mmHg (Fig. 3), pulmonary vascular resistance (PVR) of 608 dyn-s-cm⁻² and a cardiac index (CI) of 2.89 L/min per m². Consequently, pulmonary arterial hypertension (group 1 pulmonary arterial hypertension) was diagnosed by right heart catheterization (RHC). Interestingly, significant oxygen step-up was observed between the inferior vena cava (IVC) and the low level of right atrium (RA) during O₂ saturation analysis of the right heart. This findings suggested significant arterial blood shunt in this area.

Abdominal computed tomography (CT) and magnetic resonance imaging (MRI) were performed to further evaluate the multiple liver masses that were found incidentally at the patient’s local hospital. CT showed ill-defined low-density nodular lesions in the bilateral hemiliver. These lesions exhibited hyper-intensity on T1-weighted MR images and a low signal intensity on T1-weighted MR images (Fig. 4). Based on the CT and MR imaging results, initially we thought that the pulmonary arterial hypertension was caused by portal hypertension, which is known as portopulmonary hypertension associated with nodules of liver cirrhosis (LC). A percutaneous liver biopsy was performed under US guidance for histological diagnosis, which was multifocal nodular regenerative hyperplasia with no evidence of LC. Therefore, CT angiography and portal venography were performed to investigate whether intra- or extra-cardiac shunt was present and also to determine the anatomical relationship between the portal venous system and the right heart; both can cause pulmonary arterial hypertension.

CT angiography demonstrated the presence of a portocaval shunt in which the left portal vein (PV) and left hepatic vein joined and drained directly into the suprahepatic IVC without passing through the liver (Fig. 5). Portal venography revealed abnormal communication between the left PV and IVC with obliteration of the right PV (Abernethy type 1b) (Fig. 6A). The main PV and hepatic venous wedge pressure were both 6 mmHg. The superior mesenteric and splenic venous pressures were 6 mmHg and 9 mmHg, respectively. In addition, we reexamined the TTE that was not able to detect this communication at first, in which type 1 CEPS could be clearly visualized on the subcostal window (Fig. 6B).
We confirmed the diagnosis as a pulmonary arterial hypertension caused by CEPS (Abernethy type 1b) and multifocal nodular regenerative hyperplasia of the liver. However, there was no definite evidence of other cardiac, gastrointestinal or genitourinary anomalies that are also known to be associated with type 1 CEPS. The patient began inhalation of iloprost (40 μg/day) and was taught to use a nebulizer. The patient’s condition improved and he was discharged on day 7. At a 5-month follow-up appointment, his 6-min walking test improved from 380 m to 525 m, and TTE showed a reduction in RVSP from 64 mmHg to 49 mmHg.

**DISCUSSION**

Congenital extrahepatic portocaval shunts, also known as Abernethy malformations, are classified into 2 types based on the...
presence or absence of portal blood flow within the hepatic parenchyma. The first type is congenital atresia of the portal vein (end-to-side anastomosis, an Abernethy type 1 shunt), in which the superior mesenteric and splenic veins can join the IVC separately (type 1a) or as a confluence (type 1b). The second type other is hypoplasia of the portal vein with a resultant partial portocaval shunt (side-to-side anastomosis, an Abernethy type 2 shunt). Each type of shunt is associated with unique clinical
manifestations: A type 1 shunt, as was present in this patient as a type 1b shunt, is more common in females and is often complicated by congenital cardiac defects, hepatic masses, gastrointestinal and vascular anomalies (1, 6). However, a type 2 shunt is more common in males and is rarely associated with other malformations.

Pulmonary hypertension is well recognized as a complication of portal hypertension in chronic liver diseases (7, 8), but only a few cases of pulmonary hypertension have been reported that are the result of congenital extrahepatic portocaval shunt (type 1b) (2, 3). Notably, there are no previous reports of an adult male with VSD and asymptomatic multiple regenerative nodules of the liver. This patient described here was diagnosed after observation of multifocal nodular regenerative hyperplasia of the liver, and the classic symptoms related to portal hypertension were entirely absent. In the present case, it seems that gut-derived vasoactive substances, such as serotonin (5-hydroxytryptamine [5-HT]), histamine, estrogen, glucagon and endotoxin, all of which are normally metabolized in the liver, bypassed hepatic detoxification via the portocaval shunt leading to pulmonary hypertension by inducing a long-standing pulmonary vasoconstriction (9-11). Furthermore, the decrease in RVSP after iloprost treatment demonstrates that vasoconstriction played an important role in this patient.

In the reported patient, the initial impression was secondary pulmonary hypertension caused by VSD because of his previous history of surgical closure of VSD. However, there was no evidence of associated congenital cardiac defects such as, VSD, atrial septal defect (ASD), or patent ductus arteriosus (PDA). In addition, the patient had multiple liver nodules, an erroneous diagnosis of portopulmonary hypertension was made during the evaluation. Although rare, these regenerative nodules have been reported to be associated with congenital portocaval shunts, which is why we performed CT angiography and portal venography in this patient (12). Physicians should note that congenital portocaval shunt may cause pulmonary hypertension underlying multifocal nodular regenerative lesions of the liver without portal hypertension. Furthermore, if pulmonary hypertension of unknown origin is found, despite prior correction of congenital cardiac anomalies, clinicians should consider all possible causes of secondary pulmonary hypertension.

REFERENCES

1. Howard ER, Davenport M. Congenital extrahepatic portocaval shunts: the Abernethy malformation. J Pediatr Surg 1997; 32: 494-7.
2. Ohno T, Muneuchi J, Ihara K, Yuge T, Kanaya Y, Yamaki S, Haraguchi T. Pulmonary hypertension in patients with congenital portosystemic venous shunt: a previously unrecognized association. Pediatrics 2008; 121: e892-9.
3. Imamura H, Momose T, Kinabayashi H, Takahashi W, Yasaki Y, Takenaka H, Isobe M, Sekiguchi M, Kubo K. Pulmonary hypertension as a result of asymptomatic portosystemic shunt. Jpn Circ J 2000; 64: 471-3.
4. Badesch DB, Champion HC, Sanchez MA, Hoepker MM, Loyd JE, Manes A, McGoon M, Naeije R, Olscheski H, Oudiz RJ, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-66.
5. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-54.
6. Morgan G, Superina R. Congenital absence of the portal vein: two cases and a proposed classification system for portasystemic vascular anomalies. J Pediatr Surg 1994; 29: 1239-41.
7. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 17: 17-33.
8. Umeda N, Kamath PS. Hepatopulmonary syndrome and portopulmonary hypertension. Hepatol Res 2009; 39: 1020-2.
9. Liehr H, Grün M, Thiel H, Brunswig D, Rasenack U. Endotoxin-induced liver necrosis and intravascular coagulation in rats enhanced by portocaval collateral circulation. Gut 1975; 16: 429-36.
10. Parratt JR, Sturgess RM. Evidence that prostaglandin release mediates pulmonary vasoconstriction induced by E. coli endotoxin. J Physiol 1975; 246: 79P-80P.
11. Starzl TE, Watanabe K, Porter KA, Putnam CW. Effects of insulin, glucagon, and insulin/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet 1976; 1: 821-5.
12. Witters P, Maleux G, George C, Delcroix M, Hoffman I, Gewillig M, Verslype C, Monbaliu D, Aerts R, Pierre J, et al. Congenital venovenous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol 2008; 23: e390-4.